Insider Monkey
Esperion (ESPR) Highlights Inclusion of Bempedoic Acid in 2026 ACC/AHA Dyslipidemia Guidelines
📈
AI Sentiment
Highly Positive
8/10
- Home
- ESPR
as of 03-23-2026 2:29pm EST
$2.61
+$0.06
+2.35%
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | ANN ARBOR |
| Market Cap: | 793.7M | IPO Year: | 2013 |
| Target Price: | $7.60 | AVG Volume (30 days): | 4.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.11 | EPS Growth: | 60.71 |
| 52 Week Low/High: | $0.73 - $4.17 | Next Earning Date: | 03-10-2026 |
| Revenue: | $403,135,000 | Revenue Growth: | 21.31% |
| Revenue Growth (this year): | 0.69% | Revenue Growth (next year): | 10.67% |
| P/E Ratio: | -23.18 | Index: | N/A |
| Free Cash Flow: | -13093000.0 | FCF Growth: | N/A |
AI-Powered ESPR Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 19 hours ago
AI Recommendation
hold
Model Accuracy: 72.96%
72.96%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Esperion Therapeutics Inc. (ESPR)
Looker Benjamin
Sell
Chief Legal Officer
ESPR Mar 17, 2026
Avg Cost/Share
$2.70
Shares
5,708
Total Value
$15,428.72
Owned After
679,348
SEC Form 4
Koenig Sheldon L.
Sell
President and CEO
ESPR Mar 17, 2026
Avg Cost/Share
$2.72
Shares
25,578
Total Value
$69,546.58
Owned After
2,172,699
SEC Form 4
Halladay Benjamin
Sell
Chief Financial Officer
ESPR Mar 17, 2026
Avg Cost/Share
$2.71
Shares
6,424
Total Value
$17,376.92
Owned After
713,602
SEC Form 4
Looker Benjamin
Sell
General Counsel
ESPR Jan 20, 2026
Avg Cost/Share
$2.88
Shares
1,689
Total Value
$4,867.70
Owned After
679,348
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Looker Benjamin | ESPR | Chief Legal Officer | Mar 17, 2026 | Sell | $2.70 | 5,708 | $15,428.72 | 679,348 | |
| Koenig Sheldon L. | ESPR | President and CEO | Mar 17, 2026 | Sell | $2.72 | 25,578 | $69,546.58 | 2,172,699 | |
| Halladay Benjamin | ESPR | Chief Financial Officer | Mar 17, 2026 | Sell | $2.71 | 6,424 | $17,376.92 | 713,602 | |
| Looker Benjamin | ESPR | General Counsel | Jan 20, 2026 | Sell | $2.88 | 1,689 | $4,867.70 | 679,348 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Mar 10, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLMar 10, 2026 · 100% conf.
AI Prediction SELL
1D
-5.33%
$3.36
Act: -7.32%
5D
-12.77%
$3.10
Act: -18.34%
20D
-5.51%
$3.35
Act: -4.50%
Price: $3.55 Prob +5D: 0% AUC: 1.000
0001628280-26-016230
espr-20260310FALSE000143486800014348682026-03-102026-03-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 10, 2026
Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3598626-1870780 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
3891 Ranchero Drive, Suite 150 Ann Arbor, MI (Address of principal executive offices)
48108 (Zip Code)
Registrant’s telephone number, including area code: (734) 887-3903
Not Applicable Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered Common Stock, par value $0.001 per shareESPRNASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On March 10, 2026, Esperion Therapeutics, Inc. issued a press release announcing its financial results for the three months and year ended December 31, 2025 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.
The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
Exhibit No.Description
99.1 Press Release dated March 10, 2026
104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 10, 2026Esperion Therapeutics, Inc.
By:/s/ Sheldon L. Koenig Sheldon L. Koenig President and Chief Executive Officer
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLJan 12, 2026 · 100% conf.
AI Prediction SELL
1D
-5.33%
$3.36
Act: -7.32%
5D
-12.77%
$3.10
Act: -18.34%
20D
-5.51%
$3.35
Act: -4.50%
Price: $3.55 Prob +5D: 0% AUC: 1.000
0001628280-26-001764
espr-20260111FALSE000143486800014348682026-01-112026-01-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 11, 2026
Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3598626-1870780 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
3891 Ranchero Drive, Suite 150 Ann Arbor, MI (Address of principal executive offices)
48108 (Zip Code)
Registrant’s telephone number, including area code: (734) 887-3903
Not Applicable Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered Common Stock, par value $0.001 per shareESPRNASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On January 11, 2026, Esperion Therapeutics, Inc. issued a press release and released its management presentation for the upcoming Annual J.P. Morgan Healthcare Conference announcing preliminary 2025 results and the following financial guidance for the fiscal year ending December 31, 2026, which guidance is based on management’s current expectations for the business: (i) research & development expenses are expected to be in the range of $40 million to $50 million; (ii) selling, general and administrative expenses are expected to be in the range of $170 to $195 million; and (iii) operating expenses are expected to be in the range of $210 million to $245 million. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 2.02 by reference. Selected slides from the Company’s presentation are attached as Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.
The information in this Current Report on Form 8-K, Exhibit 99.1 and Exhibit 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Forward Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements about the Company’s expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as “may,” “will,” “could,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “continue,” and similar expressions, or the negative of these terms. These forward-looking statements include statements about the Company’s expected full year expenses and financial performance. Accordingly, these statements involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them. Any forward- looking statements are qualified in their entirety by reference to the factors detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and in the Company’s other reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof, and the Company disclaims any obligation or undertaking to update or revise any forward-looking statements co
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 6, 2025
0001628280-25-049866
espr-20251106FALSE000143486800014348682025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 6, 2025
Esperion Therapeutics, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3598626-1870780 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
3891 Ranchero Drive, Suite 150 Ann Arbor, MI (Address of principal executive offices)
48108 (Zip Code)
Registrant’s telephone number, including area code: (734) 887-3903
Not Applicable Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered Common Stock, par value $0.001 per shareESPRNASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 6, 2025, Esperion Therapeutics, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2025 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1.
The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
Exhibit No.Description
99.1 Press Release dated November 6, 2025
104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 6, 2025Esperion Therapeutics, Inc.
By:/s/ Sheldon L. Koenig Sheldon L. Koenig President and Chief Executive Officer
Latest Esperion Therapeutics Inc. News
ESPR Breaking Stock News: Dive into ESPR Ticker-Specific Updates for Smart Investing
Compare ESPR vs Leading Stocks
See how ESPR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ESPR Esperion Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.